Altimmune, Inc. Common Stock (ALT) is a publicly traded Healthcare sector company. As of May 21, 2026, ALT trades at $2.81 with a market cap of $544.53M and a P/E ratio of -2.79. ALT moved +3.28% today. Year to date, ALT is -31.05%; over the trailing twelve months it is -51.79%. Its 52-week range spans $2.56 to $11.16. Analyst consensus is buy with an average price target of $14.30. Rallies surfaces ALT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Altimmune Q1 Call Reveals $150M Cash Cushion and Pipeline Advancements: Altimmune reported a cash and marketable securities balance of $150 million at end of Q1 2026, extending its operational runway into late 2027. Management outlined strategic priorities to advance its NASH and vaccine programs, with a Phase 2 trial planned for its COVID-19 vaccine candidate in H2 2026.
| Metric | Value |
|---|---|
| Price | $2.81 |
| Market Cap | $544.53M |
| P/E Ratio | -2.79 |
| EPS | $-1.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.16 |
| 52-Week Low | $2.56 |
| Volume | 9.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $41.00K |
| Net Income | $-88.09M |
| Gross Margin | 0.00% |
7 analysts cover ALT: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.30.